{"disease":{"id":"endometrial","name":"endometrial"},"drugs":{"marketed":[{"drug_id":"lenvatinib","indication_name":"Endometrial carcinoma progressing after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"dostarlimab","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jemperli","generic_name":"DOSTARLIMAB","company_name":"GSK","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"chembl-chembl3301587","indication_name":"Advanced or Recurrent Endometrial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DURVALUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size."},{"drug_id":"progesterone","indication_name":"Prevention of endometrial hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PROGESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"medroxyprogesterone","indication_name":"Endometrial Hyperplasia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"medroxyprogesterone","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"goserelin","indication_name":"Endometrial Ablation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"goserelin","company_name":"Tersera","drug_phase":"marketed","molecular_target":"pituitary gonadotropin secretion","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors."},{"drug_id":"goserelin-acetate","indication_name":"Endometrial Ablation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"GOSERELIN ACETATE","company_name":"Tersera","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"Zoladex works by mimicking the body's natural hormone to reduce testosterone production."},{"drug_id":"endometrin","indication_name":"Endometrial Hyperplasia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"endometrin","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pembrolizuma","indication_name":"Endometrial carcinoma progressing after chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"dostarlimab-gxly","indication_name":"Recurrent or advanced endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of endometrial cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"megestrol-acetate","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Megace","generic_name":"MEGESTROL ACETATE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Progestin","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"progesteron","indication_name":"Endometrial Hyperplasia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoladex","indication_name":"Endometrial Ablation Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoladex","company_name":"University of Michigan Rogel Cancer Center","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"megestrol","indication_name":"Endometrial carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"megestrol","company_name":"National Center for Research Resources (NCRR)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dostarlimab-gxly","indication_name":"Endometrial Cancer - Combination Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"dostarlimab-gxly","indication_name":"Endometrial Cancer - Single Agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."}],"pipeline":[{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."}],"offLabel":[],"totalMarketed":21,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT01267851","title":"Clinical Database and Biobank of Patients With Gynecologic Neoplasms","phase":"","overall_status":"UNKNOWN","enrollment_count":1600000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05506800","title":"Guangzhou Women's Health Cohort Study (GWHCS)","phase":"","overall_status":"SUSPENDED","enrollment_count":1000000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT03285230","title":"The French E3N Prospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05142033","title":"Avera Cancer Sequencing and Analytics Protocol (ASAP)","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Avera McKennan Hospital & University Health Center","has_results":false},{"nct_id":"NCT00340262","title":"Bone Mineral Density and Subsequent Cancer Risk","phase":"","overall_status":"COMPLETED","enrollment_count":15595,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05912972","title":"Development and Management of Registry in Patients With Gynecologic Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":13500,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT00342446","title":"A Follow-up Study of Women Evaluated and Treated for Infertility","phase":"","overall_status":"COMPLETED","enrollment_count":12193,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00340600","title":"Continuation of Follow-up of DES-Exposed Cohorts","phase":"","overall_status":"COMPLETED","enrollment_count":10805,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03291275","title":"Survival Outcomes of Uterine Malignancies in Chinese Population","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05290415","title":"Host DNA Methylation for Endometrial Cancer Screening","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04096872","title":"Clinical Application of Laparo-endoscopic Single-site Surgery and Natural Orifice Transluminal Endoscopic in Gynecology","phase":"","overall_status":"UNKNOWN","enrollment_count":9000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05290922","title":"DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening","phase":"","overall_status":"UNKNOWN","enrollment_count":7150,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT00340210","title":"Extended Follow-up of Columbia, MO Serum Bank Participants","phase":"","overall_status":"COMPLETED","enrollment_count":6720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05635123","title":"A Cohort Study of Uterine Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":6200,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT00341458","title":"Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics","phase":"","overall_status":"COMPLETED","enrollment_count":6086,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00340808","title":"Molecular Staging of Endometrial Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":5492,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT07298707","title":"Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05051722","title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3110,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07148154","title":"Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"MiMARK Diagnostics, S.L.","has_results":false},{"nct_id":"NCT05697601","title":"Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools","phase":"","overall_status":"UNKNOWN","enrollment_count":2905,"lead_sponsor_name":"Hasanuddin University","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07137299","title":"POPQ Associated With Total Laparoscopic Hysterectomy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Medical University of Silesia","has_results":false},{"nct_id":"NCT05634798","title":"An Observational Study Based on Endometrial Cancer Risk Screening Model","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05387460","title":"Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT01793545","title":"Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples","phase":"","overall_status":"COMPLETED","enrollment_count":1932,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06935305","title":"OSNA Versus Ultrastaging to Detect Sentinel Lymph Node Metastasis in Endometrial Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":1922,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06284343","title":"The Gynecological Cancer Associated Thrombosis (GynCAT) Study","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04291612","title":"Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1715,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05255653","title":"Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1615,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03291106","title":"Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03538665","title":"The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04678414","title":"Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT00587886","title":"Estrogen, Diet, Genetics and Endometrial Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1315,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05242276","title":"Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Instituto de Investigacion Sanitaria La Fe","has_results":false},{"nct_id":"NCT06952504","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1123,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06096688","title":"Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction","phase":"","overall_status":"RECRUITING","enrollment_count":1120,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT05707312","title":"Staging Endometrial caNcer Based on molEcular ClAssification","phase":"","overall_status":"UNKNOWN","enrollment_count":1032,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT05687084","title":"Uterine Manipulator Versus No Uterine Manipulator in Endometrial Cancer Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":1030,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT03460483","title":"Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":1001,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06977594","title":"Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05049538","title":"Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06544837","title":"Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Inti Labs","has_results":false},{"nct_id":"NCT06354738","title":"Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Gasthuisberg","has_results":false},{"nct_id":"NCT06279832","title":"Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}